All In Biotech

Drug Trial Radar · NCT04074590

Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis

A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

23

Actual

Start

Feb 3, 2020

Primary completion

Nov 7, 2022

Study completion Nov 7, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study was to assess preliminary efficacy, safety, and tolerability of LYS006 in adult patients with mild to moderate ulcerative colitis and to determine if LYS006 has an adequate clinical profile for further development in this indication.

Conditions

  • Colitis, Ulcerative

Interventions

  • LYS006Drug

    capsule for oral use

  • PlaceboDrug

    capsule for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Remission Rate at the End of the Study TreatmentTime frame: Week 8

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Prague, Czech Republic, Czechia

  • Novartis Investigative Site

    Zlín, Czech Republic, Czechia

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Poznan, Poland

  • Novartis Investigative Site

    Nowy Targ, Lesser Poland Voivodeship, Poland

  • Novartis Investigative Site

    Warsaw, Masovian Voivodeship, Poland

  • Novartis Investigative Site

    Novosibirsk, Russia

  • Novartis Investigative Site

    Košice, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.